• Loading stock data...
Est. 2004

Wednesday 03/6/2019

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Clinical Trials

  • 1:55 PM

    Financing Enables Cannabinoid Innovator to Continue Phase I-II Trials Of Numerous Intellectual Property (IP) Protected Cannabinoid-Based Products for Multiple Indications SAN DIEGO, CA– AXIM, MJNA, (Marketwired – October 26, 2016) – Medical Marijuana, Inc. (OTC PINK: MJNA) today announced that its portfolio company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, has secured private funding to continue its pharmaceutical clinical trials program in cannabinoid research and development for multiple indications. AXIM® Biotech’s most

    Read more
  • 3:19 PM

    DMPI to Begin Trading on NASDAQ Capital Market on July 12, 2016 VANCOUVER, British Columbia and MENLO PARK, Calif., July 11, 2016, DMPI, /PRNewswire/ — DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (“DelMar” and the “Company”), a company focused on developing and commercializing proven cancer therapies in new orphan drug indications, announced today that it has received approval from the Nasdaq Stock Market LLC (“NASDAQ”) for the listing of its common stock on the NASDAQ Capital Market. DelMar’s common stock will begin

    Read more
  • 2:00 PM

    ORLANDO, FL– IMUN, (Marketwired – Apr 21, 2016) – Immune Therapeutics Inc. (OTCQB: IMUN) today announced that they have signed a binding Letter of Intent to acquire Chinese Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, Immuno-Oncology patents (pending), manufacturing technology, and clinical data of the aforementioned therapies from Super-T Cell Cancer Company (“STCC”) a newly formed corporation. “This CAR-T cell technology licensing further accelerates IMUN’s growth in the Immuno-Oncology field as we evaluate paths to commercialization both in

    Read more
  • 3:06 PM

    Company is Currently Preparing IND for New Cancer Immuno-Therapy Drug SAN DIEGO, February 24, 2016, RGBP /PRNewswire/ — Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today completion of experiments, in collaboration with Dr. Santosh Kesari, demonstrating immunological mechanisms of its novel NR2F6 gene silencing approach. Subsequent to these experiments, the Company has begun the process of compiling an Investigational New Drug Application (IND) with the FDA for testing of this approach in cancer patients. Dr. Kesari is Director

    Read more
  • 3:44 PM

    NEW YORK, Feb. 10, 2016, DCTH, /PRNewswire/ — Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that patient enrollment has begun in the Company’s Phase 3 clinical trial:  “A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma” (the FOCUS Trial). The first patient was evaluated and randomized into

    Read more
  • 3:38 PM

    CEGX Reports Near Record Quarterly Performance ABILENE, TX– OTCQB, CEGX,(Marketwired – Aug 25, 2015) – Cardinal Energy Group, Inc. (“Cardinal Energy” or “the Company”) (OTCQB: CEGX) is pleased to report its best “EBITDA” (earnings before interest, taxes, depreciation and amortization) quarter since the company was founded. EBITDA for the quarter ended June 30, 2015 was $541,491 compared to a negative $925,898 for the quarter ended June 30, 2014. Operating revenues surged to $660,444 in the current period compared to $59,920

    Read more
Public Wire Banner